the Company focused to develop a stem cell therapy business for the treatment of congestive heart failure and peripheral artery disease. The Company’s therapy will utilize a process to identify and process adult stem cells found in a patient’s blood. These adult stem cells are grown into large numbers in vitro (outside the body) and then encouraged to differentiate into angiogenic precursor cells or blood vessel forming cells for the treatment of congestive heart failure.